Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) Trial

NCT05223803 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT05223803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05223803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) Trial
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Recruiting
Start date
October 18, 2022
Completion date
July 31, 2029
Enrollment
122 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic disease, prostate cancer